Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06511141 · ClinicalTrials.gov registry record · NA
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
A NA study of Prostate Cancer and Overactive Bladder, sponsored by Axonics.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 19
- Study locations
NCT06511141: Recruiting NA study of Prostate Cancer and Overactive Bladder, sponsored by Axonics.
NCT06511141 is a NA study of Prostate Cancer and Overactive Bladder that is actively recruiting participants, run by Axonics. The registered enrollment target is 150 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower). The trial reports 19 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06511141, a NA study of Prostate Cancer and Overactive Bladder, is actively recruiting participants, sponsored by Axonics.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 19
- Study locations
Study Summary
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
Primary Outcome
Device related, procedure-related and all serious adverse events
Conditions Studied
Interventions
- DEVICE Axonics SNM System
Study Locations (19)
Alabama
- University of Alabama at Birmingham - Birmingham
- Urology Associates - Fairhope
California
- El Camino Health - Mountain View
- Tri Valley Urology - Murrieta
Florida
- University of Miami - Miami
- Advanced Urology Institute - Oxford
Louisiana
- Louisiana State University - New Orleans
- WK Clinical Research - Shreveport
Texas
- Urology Partners of North Texas (UPNT) - Arlington
- Texas Oncology - Houston
Arizona
- Mayo Clinic - Scottsdale
Maryland
- Anne Arundel Urology - Annapolis
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2028-03 |
| Phase | NA |
What NCT06511141 shows while recruiting
NCT06511141 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower).
The record links to 6 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Axonics SNM System is the first listed.
NCT06511141 lists 19 locations in 14 states (Alabama, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06511141 about?
NCT06511141 is a clinical study titled "Sacral Neuromodulation for Male Overactive Bladder (MOAB)". To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
What is the current status of trial NCT06511141?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2024-10-22. Estimated completion is 2028-03.
What conditions does trial NCT06511141 study?
This clinical trial studies the following conditions: Prostate Cancer, Overactive Bladder, Benign Prostatic Hyperplasia, Prostatectomy, Urinary Frequency.
What interventions are being tested in trial NCT06511141?
The interventions under investigation include: Axonics SNM System (DEVICE).
Who is sponsoring clinical trial NCT06511141?
This trial is sponsored by Axonics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06511141 being conducted?
This trial has 19 study locations across Alabama, Arizona, California, Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06511141's enrollment target sits among peer trials
150 260th of 735 higher than 464 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02455479 · 150 participants · Phase 1
Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI